| P1 | The identification of potent anti-tumor antibodies for ADC therapeutics from patients undergoing immunotherapy | Alexander Scholz, PhD; Jerald Aurellano; Michael Harbell, MS PhD; Danhui Zhang, MD PhD; Samantha O'Connor; May Sumi, BS; Beatriz Millare, BS; Felix Chu, MS; Sheila Fernandez; Cathrin Czupalla; Iraz T. Aydin, PhD; Amy Manning-Bog, PhD; Yvonne Leung, BS, PhD; Kevin Williamson, BS PhD; Chantia Carroll; Dongkyoon Kim, BS PhD; Xiaomu Chen, MS PhD; Sean M. Carroll, BS, PhD; Ish Dhawan, PhD; Ngan Nguyen, BS PhD; Shweta Thyagarajan; Mark Whidden; Gregg Espiritu Santo, BS PhD; Nicole Haaser, MS; Hibah Mahmood; Guy Cavet, PhD; Lawrence Steinman, MD; Tito A. Serafini, PhD; Wayne Volkmuth, BS PhD; Jonathan Benjamin, MD, PhD; William H. Robinson, MD; Norman M. Greenberg, PhD; Daniel Emerling, PhD; Jeff DeFalco | Antibody; B cell; Bioinformatics; Tumor antigens |
| P2 | Intratumoral application of hu14.18-IL2 for treatment of GD2+ pediatric malignancies: A novel immunotherapeutic approach aiming at in-situ vaccination | Romana Gugenberger, PhD; Zachary S. Morris, MD, PhD; Oliver Mutschlechner; Paul M. Sondel, MD, PhD; Hans Loibner, PhD | Antibody; Cytokine; Pediatric tumors; Solid tumors; Vaccine |
| P3 | Evaluating antibody-mediated cellular cytotoxicity and potency of antibody-drug conjugates within three-dimensional tumor models | Chris Langsdorf, BS; Bhaskar S. Mandavilli, PhD; Yi-Zhen Hu; Aimei Chen, Bachelor of Science; Marcy Wickett | Adoptive immunotherapy; Antibody; NK/NK T cell; Solid tumors; T cell; Tumor microenvironment |
| P4 | PBD-based anti-MICA/B antibody drug conjugate with a dual mechanism of action: direct tumor cell killing and restoration of NKG2D-mediated immunosurveillance | Florence Lhospice, Pharm D; Laurent Pouyet, PhD; Ester Morgado; Romain Remark, PhD; Delphine Bregeon, PhD; Adeline Montbel; Nadia Anceriz; Mathieu Blery, PhD; Ariane Morel, PhD; Manel kraiem; Kenneth Crook; Yannis Morel, PhD; Eric Vivier; | Antibody; Immune monitoring; Tumor infiltrating lymphocytes (TILs); Tumor antigens |
| P5 | Anti-CD38 immunotherapy kills Treg (CD4+CD25+FoxP3+CD38hi) and Breg (CD19+CD24+CD38hi) cells and restores the anti-tumor T-cell repertoire in chronic lymphocytic leukemia (CLL). | Alak Manna, PhD; Sonikpreet Aulukh, MD; Laura J. Lewis-Tuffin, PhD; Taimur Sher, MD; Sikander Ailawadhi, MD; Rami Manuchakian, MD; Asher A. Chanan-Khan; Aneel Paulus, MD; Alak Manna, PhD; | Antigen presenting cells; B cell; Immune suppression; Leukemia/Lymphoma; T cell; Targeted therapy; Tumor microenvironment |
| P6 | Anti-CD38 immunotherapy kills Treg (CD4+CD25+FoxP3+CD38hi) and Breg (CD19+CD24+CD38hi) cells and restores the anti-tumor T-cell repertoire in chronic lymphocytic leukemia (CLL). | Alak Manna, PhD; Sonikpreet Aulakh, MD; Laura J. Lewis-Tuffin, PhD; Taimur Sher, MD; Sikander Ailawadhi, MD; Rami Manuchakian, MD; Asher A. Chanan-Khan; Aneel Paulus, MD; | B cell; Immune adjuvant; Immune suppression; Immune tolerance; Immune toxicity; Leukemia/Lymphoma; Monocyte/Macrophage |
| P7 | Potent tumor-directed T cell activation and tumor inhibition induced by a 4-1BB x 5T4 ADAPTIR™ bispecific antibody | Michelle H. Nelson, PhD; Gabriele Blahnik-Fagan; Robert Bader; Doreen Werchau, BS; Anneli Nilsson; Lill Ljung; Jeannette Bannink, BS; Danielle Mitchell; Lynda Misher; Catherine McMahan; Maria Askmyr; Anna Dahlman; Peter Ellmark, PhD; Gabriela Hernandez-Hoyos; Sara Fritzell; Sara Fritzell | Antibody; Costimulation; NK/NK T cell; T cell; Targeted therapy |
| P8 | Single-cell proteomic analysis of T cells stimulated by Bi-specific T-cell Engagers (BiTEs) shows robust and unique polyfunctional secretion profile | Sean G. Mackay, MBA; Patrick Paczkowski; Brianna Flynn, MS; Kevin Morse; Tiffany A. Coupet, BS; Claire Godbersen, B.S.; Charles L. Sentman; Jing Zhou, MD, PhD; | Antibody; Bioinformatics; Biomarkers; Chemokine; Cytokine; Proteomics; T cell; Targeted therapy; Tumor antigens |
| P9 | Identification and functional profiling of PD-L1 targeted engineered toxin bodies for antigen seeding technology and redirection of T cell response to tumors | Brigitte Brieschke, BS; Sara LeMar; Garrett L. Robinson; Aimee Iberg, Ph.D.; Shaoyou Chu, Ph.D.; Jack P. Higgins, Ph.D.; Erin K. Willert, Ph.D.; Hilario J. Ramos, Ph.D.; | Adoptive immunotherapy; Checkpoint blockade; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs) |
| P10 | Local radiation with intratumoral anti-disialoganglioside (anti-GD2) and interleukin-2 (IL2) induces significant tumor responses with immunologic memory in a syngeneic murine NXS2 neuroblastoma model | Julie S. Voeller, MD; Amy K. Erbe, PhD; Kayla Rasmussen, Ms; Jacob Slowinski, Mr.; Sabrina VandenHeuvel; Ravi Patel, MD, PhD; Hans Loibner, PhD;Stephen D. Gillies, PhD; Jacquelyn A. Hank, PhD; Alexander L. Rakhmilevich, MD, PhD; Zachary S. Morris, MD, PhD; Paul M. Sondel, MD, PhD; Julie S. Voeller, MD; Julie S. Voeller, MD; | Antibody; Pediatric tumors; Radiotherapy; Solid tumors; Targeted therapy; Tumor antigens |
| P11 | A CD25-targeted pyrrolobenzodiazepine dimer-based antibody-drug conjugate shows potent anti-tumor activity in pre-clinical models of solid tumors either alone or in combination with a PD-1 inhibitor | Francesca Zammarchi, PhD; Karin Havenith, PhD; Francois Bertelli; Balakumar Vijayakrishnan; Patrick H. van Berkel, Ph.D; | Antibody; Checkpoint blockade; Regulatory T cell (Treg cell); Solid tumors; Targeted therapy; Tumor infiltrating lymphocytes (TILs) |
